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Abstract
The cancer Biomedical Informatics Grid (caBIG) was launched in 2003 by the US National Cancer Institute with the aim of connecting 
research teams through the use of shared infrastructure and software to collect, analyse and share data. It was an ambitious project, 
and the issue it aimed to address was huge and far-reaching. With such developments as the mapping of the human genome and the 
advancement of new technologies for the analysis of genes and proteins, cancer researchers have never produced so much complex 
data, nor have they understood so much about cancer on a molecular level. This new ‘molecular understanding’ of cancer, according to 
the caBIG 2007 ‘Pilot Report’[1], leads to molecular or ‘personalised’ medicine being the way forward in cancer research and treatment, 
and connects basic research to clinical care in an unprecedented way. But the former ‘silo-like’ nature of research does not lend itself 
to this brave new world of molecular medicine—individual labs and institutes working in isolation, “in effect, as cottage industries, each 
collecting and interpreting data using a unique language of their own”[2] will not advance cancer research as it should be advanced. The 
solution proposed by the NCI in caBIG was to produce an integrated informatics grid (‘caGrid’) to incorporate open source, open access 
tools to collect, analyse and share data, enabling everyone to use the same methods and language for these tasks.
caBIG is primarily a US-based endeavour, and though the tools are openly available for users worldwide, it is in US NCI-funded cancer 
centres that they have been actively introduced and promoted with the eventual hope, according to the pilot report, of being able to do the 
same worldwide. caBIG also has a collaboration in place with the UK organisation NCRI to exchange technologies and research data. The 
European Association for Cancer Research, a member association for cancer researchers, conducted an online survey in January 2011 
to identify the penetration of the ambitious caBIG project into European laboratories. The survey was sent to 6396 researchers based in 
Europe, with 764 respondents, a total response rate of 11.94%.
Published: 03/10/2011  Received: 18/08/2011
ecancer 2011, 5:225 DOI: 10.3332/ecancer.2011.225
Copyright: © the authors; licensee ecancermedicalscience. This is an Open Access article distributed under the terms of the Creative 
Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction 
in any medium, provided the original work is properly cited.ecancer 2011, 5:225
www.ecancermedicalscience.com 2
P
o
l
i
c
y
European survey
A list of caBIG branded tools was given, along with a link to each tool’s web page, and respondents were asked to state how often they 
used each one: ‘Often’, ‘Sometimes’ or ‘Never’. If they use the tool, respondents were asked to rate it out of 5 (from ‘1 = very poor’ to ‘5 = 
very good’) and suggest any improvements that could be made.
Results
Frequency of use
The tools are listed in descending order in Figure 1 according to the percentage of respondents who answered that they use the tool ‘Often’. It 
clearly shows that the majority of respondents (ranging between 84.81% and 95.99%) never use the caBIG tools they were asked about. The 
most frequently used tool, GenePattern, boasts just 2.01% of respondents using it often, while 84.81% never use it. GenePattern is not one of 
Figure 1: Frequency of use of the caBIG tools.www.ecancermedicalscience.com 3
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the tools developed exclusively for caBIG: it was developed by the Broad Institute in 2004, accessible from the Broad Institute website, and 
was made compatible with the caBIG architecture as one of several collaborations: its availability elsewhere and number of collaborations may 
help to explain its popularity.[3,4] One possible contributing reason for the lower usage of some of the tools could be the fact that many, such as 
cancerBench-to-Bedside, NCI Protege, caIntegrator, caBIG Integration Hub and the caBIG Vocabulary Knowledge Center, all at the lower end 
of the usage scale, are designed to be used alongside other caBIG applications, which limit their potential user base to only those who choose 
to use other tools from caBIG. Because of the intention of the project, to bring together all cancer data in an integrated environment, with some 
caBIG tools, the outward appearance seems to be ‘all or nothing’—if a user wishes to adopt them, they should do so alongside other caBIG tools, 
which may be off-putting to some, especially if their lab has already purchased commercial software to do the same tasks. Though all of the caBIG 
tools are laudably produced in open source code, with an open source license that allows users to adapt them to their own systems and existing 
software, not all laboratories have the resources or programming knowledge to do this. In November 2010, the NCI Board of Scientific Advisors 
created an ad hoc working group to provide an independent review of the caBIG program. Their final report, published in March 2011, mentioned 
that “a significant level of technical knowledge and dedicated local informatics resources are required to make the tools useful in a cancer center’s 
research environment and to support their customization, adoption and use. This is very frustrating to potential users.”
Perceived quality of the tools
In Figure 2, though the results show that the tools in question are used very little by the survey respondents, it also shows a high level of 
regard from those who do use them. Due to the low usage previously demonstrated, the sample sizes for this question were small (see 
Figure 2: Perceived quality of the caBIG tools.ecancer 2011, 5:225
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‘Total respondents’ column on the right). Though there is a clear hierarchy of which tools more highly rated, it is also clear that all of the 
tools are well regarded by the respondents who use them, with a small minority in each case rating a tool as ‘poor’ or ‘very poor’.
Of course, there is some inherent bias in these responses, as the respondents to this question already use the tools in question. Unless 
compelled to use them by their institutes or by financial necessity, the very fact that they use a certain tool indicates that it must be of some 
use to them. The only way to correct this bias would be to conduct a thorough testing of the various tools by researchers who have never 
used them, and then solicit a rating based on this assessment.
In addition to receiving the most use, GenePattern also received the highest average rating by the respondents. This result was echoed 
in the March working group 2011 report, where GenePattern received the most positive reports from interviewees.[5]
Average rating vs. frequency of use
In order to better analyse the caBIG tools’ usage and rating, a scatter graph was created to compare these two (Figure 3). The frequency 
of use responses ‘Often’, ‘Sometimes’ and ‘Never’ were given numerical values in order to reach a weighted average figure for each tool. 
These numerical values have not been shown on the X axis as it is a meaningless scale: for actual frequency of use figures, see the 
‘Frequency of use’ chart. In the above graph, the average frequency of use figure was plotted against the average rating out of 5 (1 = very 
poor to 5 = very good) for each tool.
In general, the trend is that the higher-rated tools are used more and the lower-rated tools are used less. However, the graph identifies 
some anomalies: caArray receives the lowest average rating by its users, an average of 3.55 out of 5, and yet is the fourth most frequently 
used. The fact that caArray is directly accessible from the Web, with no download or sign-in required, may be one reason for its frequent 
use. Conversely, the caBIG Vocabulary Knowledge Center is one of the highest rated tools and also one of the least used. The niche mar-
ket for the tool may explain this: its web page describes its purpose as “providing access and support to those individuals and institutions 
interested in making use of or extending caBIG® tools and other vocabulary tools”[6], thus making it potentially very useful, but only to a 
select few who are interested in working with or developing caBIG or other vocabulary tools.
Figure 3: Average rating vs. frequency of use.www.ecancermedicalscience.com 5
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Free text: Improvements
After asking to rate each tool if they used it, a free text box was provided to suggest any improvements that could be made. Few comments 
were received, which are tabulated below.
Please suggest any improvements that could be made 
caArray—Array Data Management System
A good tool
My students use it
geWorkbench
Seems an easy tool for array analysis
caTissue Suite
Useful for overall storage/retrieval of complex biospecimens/case series. Maybe less so for smaller numbers of specimens.
We will use it in the near future
Cancer Genome-Wide Association Scan (caGWAS)
Still learning how to use the program
We have preliminary information, plan to use it more frequently in the near future
National Biomedical Imaging Archive
The integration of images of biomedical research with genomics data is a very potent thus intuitive method
Registration should be a quicker process—we often work on tight deadlines!
caIntegrator
Sometimes, array analyses require a broad computing language knowledge such as R. This tool may help these people not 
familiar with this computing abilities.
cancerBench-to-Bedside (caB2B)
As integrative tool can be very useful
GenePattern
Will get into it in the near future
It would be great to have a few example input files for every type of plug in
Database is represented with included data, not with real situation
caBIG Integration Hub (formerly caXchange)
Plan to use it this yearecancer 2011, 5:225
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NCI Protégé
 [No Responses]
caBIG Vocabulary Knowledge Center (LexEVS Server; LexEVS and EVS APIs; LexBIG)
 [No Responses]
BiomedGT Wiki and LexWiki
Haven’t used enough to have a good idea of rating
General comments
Comment on this whole survey—most of the tools mentioned, I have never heard of. I might use them if I knew about them 
and what they do. The BiomedWiki tool I came across from Google.
I should say although I don’t use these tools directly, I have a team of researchers that will find such tools useful.
I was never aware of the availability of these tools until now. Definitely will give them a shot.
I do thank you for valuable information of the mentioned NCI tools which I have never heard about before.
Conclusions
The survey results show a widespread lack of usage and knowledge of the caBIG research-oriented tools in Europe. Those who chose to 
comment on the survey overall said that they had never heard of them. With a large number of open access biomedical tools being devel-
oped across the world and within Europe by institutes and collaborative partnerships, especially in the burgeoning field of bioinformatics,[7] 
this is unsurprising. While the NCI’s plan to introduce the caBIG network and tools in the US involved promoting, supporting and sub-
sidising their introduction at NCI-funded institutes, European institutes and scientists received no such promotion, so the array of tools 
offered under the caBIG umbrella appears to have gone largely unnoticed. This limited uptake of the tools does not appear to be confined 
to Europe. According to the final report of the NCI Scientific Advisory Board’s working group on caBIG, “the majority of the 32 Bench-
to-Bench research tools developed by caBIG® under contracts with commercial or academic investigators have had very limited usage 
and, as a result, have not generated significant impact in the scientific community.” The working group’s recommendations include a 
moratorium on all current software development and a 1-year moratorium on all future projects. caBIG has now put out an request for 
information to have these tools moved into the care and development of the public sector. Whilst this programme has been a Federally 
mandated project aimed at the domestic market, there is clearly an opportunity for better global dissemination irrespective of who even-
tually becomes their curator. For Europe, the public policy message is clear. Bioinformatic developments need better dissemination and 
marketing to the cancer research community and more work needs to be put into establishing ongoing needs assessments from the broad 
church of cancer research.
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